Political Pressure Mounts as Trump Targets Weight-Loss Drug Pricing

The weight-loss pharmaceutical sector experienced significant turbulence following a social media post from former President Donald Trump. His call for substantial price reductions on popular GLP-1 medications sent shockwaves through the multi-billion dollar market, directly impacting industry leaders Eli Lilly and Novo Nordisk. This political intervention raises fundamental questions about the sustainability of premium pricing models in the obesity treatment space.

Financial markets responded swiftly to Trump’s proposal that diabetes and weight-management drugs like Ozempic should be priced around $150 monthly. The announcement triggered immediate sell-offs, with Novo Nordisk shares declining 7% while Eli Lilly equity fell more than 4%. This dramatic response underscores how quickly political developments can reshape pharmaceutical valuations.

Eli Lilly’s direct-to-consumer pricing strategy faces particular scrutiny.... Read more...